RT info:eu-repo/semantics/article
T1 Prognostic significance of amino acid and biogenic amines profiling in chronic kidney disease
A1 Gervasini, Guillermo
A1 Verde Rello, Zoraida
A1 González, Luz María
A1 Chicharro, Celia
A1 González Rodríguez, Laura
A1 Fernández Araque, Ana María
A1 Mota Zamorano, Sonia
A1 Cancho, Bárbara
A1 Pérez Hernández, Alberto
A1 García López, Virginio
A1 Bandrés, Fernando
A1 Robles, Nicolás R.
K1 Chronic kidney disease
K1 Kidneys - Diseases
K1 Riñones - Enfermedades
K1 Nephrology
K1 Amino acids
K1 Biogenic amines
K1 Aminas
K1 Metabolites
K1 Molecular biology
K1 3205.06 Nefrología
K1 2302.02 Aminoácidos
K1 32 Ciencias Médicas
K1 2302.21 Biología Molecular
AB There is a pressing need for more precise biomarkers of chronic kidney disease (CKD). Plasma samples from 820 subjects [231 with CKD, 325 with end-stage kidney disease (ESKD) and 264 controls] were analyzed by liquid chromatography with tandem mass spectrometry (LC-MS/MS) to determine a metabolic profile of 28 amino acids (AAs) and biogenic amines to test their value as markers of CKD risk and progression. The kynurenine/tryptophan ratio showed the strongest correlation with estimated glomerular filtration rate values (coefficient = −0.731, p < 0.0001). Models created with orthogonal partial least squares-discriminant analysis (OPLS-DA) containing the metabolic signature showed a high goodness of fit and predictability for controls/CKD (R2X:0.73:R2Y:0.92:Q2:0.92, p < 0.0001) and lower values for CKD/ESKD (R2X:0.56:R2Y:0.59:Q2:0.55, p < 0.0001). Based on generated VIP scores, the most relevant markers for segregating samples into control/CKD and CKD/ESKD groups were citrulline (1.63) and tryptophan (1.47), respectively. ROC analysis showed that the addition of the metabolic profile to a model including CKD classic risk factors improved the AUC from 86.7% (83.6–89.9) to 100% (100–100) for CKD risk (p < 0.0001) and from 63.0% (58.2–67.8) to 96.5% (95.3–97.8) for the risk of progression from CKD to ESKD (p < 0.0001). Plasma concentrations of AAs and related amines may be useful as diagnostic biomarkers of kidney disease, both for CKD risk and for progression of CKD patients to ESKD.
PB MDPI
SN 2227-9059
YR 2023
FD 2023
LK https://uvadoc.uva.es/handle/10324/67005
UL https://uvadoc.uva.es/handle/10324/67005
LA eng
NO Biomedicines, 2023, Vol. 11, Nº. 10, 2775
NO Producción Científica
DS UVaDOC
RD 22-may-2024